Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C6 Ceramide NanoLiposome in RR-AML
NCT04716452Phase 1Recruiting
- Sponsor
- PendreaBio
- Start
- Oct 2025
- Primary completion
- Jan 2027
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ceramide nanoliposome in acute myeloid leukemia (AML), sponsored by PendreaBio. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 24 weeks and 12 more. Started Oct 2025; status: recruiting.
02
Drugs
Ceramide nanoliposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04716452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716452.